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Abstract 
Background: Older patients with longstanding type 1 diabetes have high cardiovascular disease (CVD) risk such that 
statin therapy is recommended independent of prior CVD events. We aimed to determine self-reported CVD preven-
tion guideline adherence in patients with longstanding diabetes.
Research design and methods: 309 Canadians with over 50 years of type 1 diabetes completed a medical ques-
tionnaire for presence of lifestyle and pharmacological interventions, stratified into primary or secondary CVD preven-
tion subgroups based on absence or presence of self-reported CVD events, respectively. Associations with statin use 
were analyzed using multivariable logistic regression.
Results: The 309 participants had mean ± SD age 65.7 ± 8.5 years, median diabetes duration 54.0 [IQR 51.0, 
59.0] years, and HbA1c of 7.5 ± 1.1 % (58 mmol/mol). 159 (52.7 %) participants reported diet adherence, 296 (95.8 %) 
smoking avoidance, 217 (70.5 %) physical activity, 218 (71.5 %) renin-angiotensin-system inhibitor use, and 220 
(72.1 %) statin use. Physical activity was reported as less common in the secondary prevention subgroup, and current 
statin use was significantly lower in the primary prevention subgroup (65.5 % vs. 84.8 %, p = 0.0004). In multivariable 
logistic regression, the odds of statin use was 0.38 [95 % CI 0.15–0.95] in members of the primary compared to the 
secondary prevention subgroup, adjusting for age, sex, hypertension history, body mass, HbA1c, cholesterol, micro-
vascular complications, acetylsalicylic acid use, and renin-angiotensin system inhibitor use.
Conclusion: Despite good self-reported adherence to general CVD prevention guidelines, against the principles 
of these guidelines we found that statin use was substantially lower in those without CVD history. Interventions are 
needed to improve statin use in older type 1 diabetes patients without a history of CVD.
Keywords: Type 1 diabetes, Cardiovascular disease, HMG-CoA reductase inhibitor (3-hydroxy-3-methyl-glutaryl-CoA 
reductase), Statin, Adherence
© 2016 Bai et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cardiovascular Diabetology
*Correspondence:  BPerkins@mtsinai.on.ca 
†Johnny W. Bai and Geneviève Boulet are co-first authors
1 Division of Endocrinology and Metabolism, Department of Medicine, 
University of Toronto, Leadership Sinai Centre for Diabetes, Mount Sinai 
Hospital, L5-210, 60 Murray Street, Mail Box 16, Toronto, ON M5T 3L9, 
Canada
Full list of author information is available at the end of the article
Page 2 of 10Bai et al. Cardiovasc Diabetol  (2016) 15:14 
Background
Cardiovascular disease (CVD), which includes myocar-
dial infarction, coronary artery disease (CAD), stroke, 
and peripheral vascular disease, is often cited as the pri-
mary cause of mortality in type 1 diabetes mellitus [1–4]. 
Though it has been suggested that people with diabetes 
have a two to fourfold excess risk of developing CVD, in 
the context of type 1 diabetes the magnitude of this risk 
approaches tenfold [5–7]. The etiology for amplifica-
tion of lifetime CVD risk in type 1 diabetes may relate 
to longer duration of exposure to hyperglycemia [7, 8] in 
part owing to relatively younger age at diagnosis. Thus, 
older patients with long duration of type 1 diabetes are a 
unique group with extremely high lifetime risk of CVD.
More intensive cardiovascular protection measures 
are recommended for older patients with longstanding 
diabetes regardless of their CVD history, particularly 
with regard to pharmacotherapy for lipid control [9, 10]. 
Clinical guidelines on vascular protection in diabetes rec-
ommend the use of 3-hydroxy-3-methylglutaryl-coen-
zyme A reductase inhibitors (commonly referred to as 
“statins”) in patients who are over age 40, have long dura-
tion of diabetes, or are younger but have existing micro-
vascular complications or additional risk factors [10–12]. 
The benefits of statin use and lowering LDL cholesterol 
(LDL-C) in diabetes are strongly supported by studies 
which demonstrate the effectiveness of statins in reduc-
ing risk of vascular events and mortality regardless of 
prior CVD history [13, 14]. Other general strategies for 
vascular protection include smoking cessation, dietary 
modification, regular physical exercise, maintenance of 
optimal glycemic control, blood pressure, and weight, 
and the use of renin-angiotensin system (RAS) inhibitors 
such as angiotensin-converting enzyme inhibitors (ACEi) 
or angiotensin receptor blockers (ARB). The evidence 
that justifies acetylsalicylic acid use is focused mainly on 
secondary rather than primary CVD prevention [11, 12]. 
Ultimately, in the context of long diabetes duration and 
older age, a key emphasis of guidelines is the use of phar-
macotherapy—in particular statin therapy—independent 
of CVD history.
Despite strong evidence for CVD primary prevention 
strategies, studies in general practice settings have noted 
low adherence to these guidelines, possibly due to the 
nature of preventative rather than therapeutic interven-
tions, expense, concerns about efficacy and side-effects, 
and limitations in physician-patient relationships [15–
18]. Suboptimal statin adherence has been shown in CVD 
primary prevention (those without history of CVD), with 
long duration of therapy, and in elderly patients. Under-
treatment substantially increases the risk of adverse 
cardiovascular outcomes and mortality [18–23]. To our 
knowledge, there are no studies which examine attention 
to CVD prevention guidelines, and specifically statin use, 
in patients with longstanding type 1 diabetes.
We aimed to determine whether guideline adherence 
and self-reported statin use differed between those with 
and without history of CVD in the baseline phase of the 
Canadian Study of Longevity in Type 1 Diabetes cohort 
consisting of patients with 50  years or more of type 1 
diabetes at uniformly high risk of CVD. Disparity in the 
comparison between those with and without CVD his-
tory may indicate suboptimal implementation of current 
clinical practice guidelines and a disregard for longstand-
ing diabetes as a fundamental CVD risk factor.
Research design and methods
Study overview
This study was conducted as a secondary analysis of the 
baseline data from the Canadian Study of Longevity in 
Type 1 Diabetes cohort (JDRF operating grant 17-2013-
312). The goal of this analysis was to describe adherence 
to CVD prevention guidelines—with an emphasis on 
self-reported statin use—in Canadians living with type 1 
diabetes for 50 years or more.
Participant recruitment
Between April 2013 and December 2014, patients were 
contacted across Canada through public advertisements, 
social media, and mailings to health care professionals 
including primary care physicians, endocrinologists, and 
pharmacists. Akin to other cohorts, our study included 
patients with a history of at least 50  years of insulin 
dependence, as acknowledged through medical docu-
mentation or corroboration by a family member [24, 25]. 
For the Canadian Study of Longevity in Type 1 Diabe-
tes, we anticipated a total cohort sample size of approxi-
mately 300 participants based on Canadian 1962 census 
data and contemporaneous age-specific incidence rates 
of type 1 diabetes and survival curves [26, 27]. A total 
of 427 people initially contacted us by toll free number, 
mail, or e-mail, and 386 eligible participants agreed to 
participate. By the time of analysis, 309 questionnaires 
were returned and these participants were included in 
analysis. Participant flow is summarized in Fig.  1. Par-
ticipant recruitment and data entry remains ongoing. 
Participants provided written informed consent, and the 
study protocol was approved by the ethics committee of 
the Mount Sinai Hospital (Toronto, ON, Canada).
Data collection
Data were collected through a 35-page questionnaire 
in which participants were asked about their diabetes 
management, family history of CVD, lifestyle and smok-
ing habits, medication use, and history of cardiovascu-
lar disease (angina and heart attack), related surgeries 
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(cardiac/leg bypass and angioplasty), hypertension and 
other medical history including cerebrovascular disease. 
Furthermore, we obtained from participants’ healthcare 
providers recent clinical, physical, and laboratory meas-
urements including blood pressure, lipid profile, HbA1c, 
estimated glomerular filtration rate (eGFR), and fundos-
copy examination results.
Lifestyle variables included questions related to diet, 
smoking, and physical activity: Diet was assessed using 
seven questions surrounding nutrient and caloric intake, 
meal patterns, and meal content. Dietary adherence was 
defined by presence of (1) self-reported consumption of 
fruits and vegetables and (2) self-reported effort to mod-
erate consumption of dietary carbohydrates and fats. Par-
ticipants reported presence or absence of current smoking 
and physical activity, and provided body weight and height 
from which BMI was calculated. To define pharmaco-
therapy use, participants were asked to list all current 
medications, allowing determination of acetylsalicylic acid, 
statin, ezetimibe, fibrate, and RAS inhibitor use; history 
of side-effects, drug intolerance, and duration of therapy 
were not ascertained. As participants were over the age 
of 40, according to guidelines all participants were eligi-
ble for statin use [10–12]. Also according to guidelines, 
RAS inhibitor use is indicated for participants older than 
55 years, with microvascular complications, or with prior 
CVD history. Subjects meeting these criteria and report-
ing use of RASi were considered to be adherent [11].
For descriptive purposes, an “adherence index” was cre-
ated based on self-reported clinical variables and labo-
ratory results, compared to clinical practice guideline 
recommendations [10–12]. Participants were assessed 
for attainment of (1) recommended diet; (2) lack of 
smoking; (3) reported physical activity; (4) glycemic control 
[HbA1c ≤7 % (53 mmol/mol)]; (5) blood pressure control 
(≤130/80  mmHg); (6) LDL-C  ≤2.0  mmol/L; (7) mainte-
nance of optimal body weight (BMI <25.0 kg/m2); (8) self-
reported use of statin therapy for participants  ≥40  years 
of age (i.e. all study participants); (9) self-reported RAS 
inhibitor therapy for secondary prevention, age ≥55 years, 
or age  <55  years but with microvascular complications. 
Adherence was reported as frequency and proportion of 
participants who attained each recommendation. These 
recommendations were stratified into domains of lifestyle 
adherence (recommendations 1–3), clinical target adher-
ence (recommendations 4–7), and pharmacotherapy use 
(recommendations 8–9). As acetylsalicylic acid use for 
primary prevention is not unanimously supported by evi-
dence, it was not used in the adherence index.
Nephropathy was defined by the presence on laboratory 
tests of albumin to creatinine ratio (ACR) ≥2 mg/mmol or 
an age-adjusted glomerular filtration rate (GFR) <60 ml/
min [28]. Presence of retinopathy, and its classification 
as proliferative or non-proliferative, was obtained by the 
recent eye specialist examination. Presence of sympto-
matic diabetic neuropathy was determined through the 
use of the 15-item, self-administered Michigan Neuropa-
thy Screening Instrument (MNSI) questionnaire. Neurop-
athy was defined by a score ≥3 [29].
Primary and secondary prevention subgroups
Participants were stratified into primary and second-
ary prevention subgroups for comparison. The second-
ary prevention subgroup consisted of participants who 
reported any previous diagnosis of coronary artery dis-
ease, heart attack or angina, history of cardiac or leg 
angioplasty, bypass graft surgery, or cerebrovascular dis-
ease including stroke. Participants without any of these 
factors were considered to be in the primary preven-
tion subgroup. As this study was a secondary analysis of 
cohort data, there were no specific questions about cer-
ebrovascular incidents; history of such events was deter-
mined from an open-ended question for participants to 
report all known medical conditions and history.
Statistical analysis
SAS version 9.2 (SAS Institute, Cary, NC, USA) was used 
to perform statistical analysis. Descriptive characteristics 
were reported as mean ± standard deviation (SD), median 
and interquartile range (IQR), or as frequency and percent. 
Statistical comparisons between primary and secondary 
prevention subgroups were made using the Student’s t test, 
the Mann–Whitney U test, or the χ2-test, depending on the 
distribution of the variable. For the adherence index, the 
χ2-test was used to compare adherence rates between pri-
mary and secondary prevention subgroups; Cohen’s kappa 
Fig. 1 Participant flow diagram
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coefficient was used to assess agreement among each index. 
Logistic regression was performed to assess the associa-
tion of CVD history with self-reported statin use: first uni-
variable models were used to identify other participant 
characteristics that were significantly associated with sta-
tin use. In order to adjust for these potential confounders, 
these characteristics were then included as independent 
variables along with CVD history in a final multivariable 
model, with statin use as the dependent variable. Age, sex, 
and HbA1c were included a priori, as well as all significant 
predictors (p < 0.05) in univariable analyses. Multicollinear-
ity among the independent predictor variables was assessed. 
Odds ratios (OR) are reported along with their 95 % con-
fidence intervals. As a sensitivity analysis, the multivari-
able model was also run using a stepwise variable selection 
model. As a second sensitivity analysis, the logistic regres-
sion was restricted to the primary prevention subgroup. 
P-values < 0.05 were considered statistically significant. The 
sample size was estimated to have a power of 0.81 to detect 
at least a 15 % difference in proportion of statin use between 
primary and secondary prevention subgroups, based on the 
assumptions of approximately 50 % statin use [22] and 50 % 
prevalence of CVD in longstanding type 1 diabetes [24].
Missing data was assumed to be missing at random. Sys-
tolic blood pressure (SBP) and diastolic blood pressure 
(DBP) data was incomplete in that 150(49 %) of values were 
unreported in the physical exam reports from health care 
providers. For this reason, self-reported history of hyper-
tension was instead used in the multivariable model, but we 
performed a sensitivity analysis using SBP. Available-case 
analysis was used to report patient characteristics, guideline 
adherence values, and univariable screening, whereas com-
plete-case analysis was used for multivariable regression. To 
honour variations in threshold values reported by different 
international organizations that provide clinical practice 
guidelines, a sensitivity analysis was performed using higher 
HbA1c of 7.5 % (58 mmol/mol), 8.0 % (64 mmol/mol), and 
8.5 % (69 mmol/mol), blood pressure <140/90 mmHg, and 
BMI <30 kg/m2 targets as cut-offs [12, 30, 31]. Furthermore, 
as some guidelines recommend special considerations for 
statin use for patients of extreme age, we performed sensi-
tivity analysis by comparing statin use only among partici-
pants who were 75 years or younger [12].
Results
Patient characteristics are summarized in Table 1 according 
to the total cohort, primary prevention, and secondary pre-
vention subgroups. The 309 participants had a mean ± SD 
age of 65.7 ± 8.5 years and median diabetes duration of 54.0 
[IQR 51.0, 59.0] years, with 137 (44.5 %) participants being 
male and 13 (4.2  %) non-Caucasian. Notably, the primary 
prevention subgroup was significantly younger (64.3 ± 8.5 
vs. 68.5 ± 8.3 years, p < 0.001), had shorter diabetes duration 
(53.0 [50.0, 57.0] vs 57.0 [52.5, 60.5] years, p < 0.001), and 
contained a smaller proportion of males (82.0 (40.4 %) vs. 55 
(52.4 %), p = 0.045). There were no significant differences 
between primary and secondary prevention subgroups in 
elements of the family history. Clinical features are shown 
in the second section of the table. The 309 participants had 
a BMI of 25.0 [23.0, 28.2], SBP of 128.8 ± 14.9 mmHg, and 
DBP of 67.4 ± 8.9 mmHg, and 182 (60.3 %) reported his-
tory of hypertension. Of these clinical variables, relative to 
the secondary prevention subgroup, the primary preven-
tion subgroup had a lower proportion of hypertension his-
tory (111 (56.1 %) vs. 71 (68.3 %), p = 0.04). For laboratory 
report values, the whole cohort had HbA1c of 7.5 ± 1.1 % 
(58  mmol/mol), total cholesterol of 4.1  ±  0.9  mmol/L, 
and LDL-C of 2.0 ± 0.7 mmol/L. The primary prevention 
subgroup had lower HbA1c (7.4 ±  1.1 (57 mmol/mol) vs. 
7.7 ± 1.1 % (61 mmol/mol), p = 0.04), higher total choles-
terol (4.24 ± 0.92 vs. 3.95 ± 0.86, p = 0.02), lower triglycer-
ides (0.77 [0.60, 1.00] vs. 0.83 [0.66, 1.23] mmol/L, p = 0.04), 
and higher HDL-C (1.79 ±  0.52 vs. 1.58 ±  0.49  mmol/L, 
p = 0.002). The two subgroups did not differ significantly in 
LDL-C. Regarding diabetes complications, 193 (71.5 %) had 
retinopathy, 130 (42.4 %) had neuropathy, and 110 (38.6 %) 
had nephropathy. The secondary prevention group had a 
significantly higher proportion of each of these three com-
plications. Medications are presented in the final section 
of Table 1: a total of 177 (58. %) reported using acetylsali-
cylic acid, 220 (72.1 %) statin, 23 (7.5 %) ezetimibe, 1 (0.3 %) 
fibrate, and 218 (71.5  %) RAS inhibitor. Of these, the pri-
mary prevention group had markedly lower acetylsalicylic 
acid, statin, and ezetimibe use than the secondary preven-
tion subgroup.
The distribution of cardiovascular conditions is pre-
sented in Fig. 2. Of the entire cohort, 105 (34 %) had cardi-
ovascular conditions (and were included in the secondary 
prevention subgroup). Within this subgroup, 78 (75.0  %) 
reported history of heart attack or angina, 52 (50.0 %) had 
cardiac bypass surgery, 40 (41.2 %) had cardiac angioplasty, 
16 (16.5 %) had leg bypass surgery, and 21 (21.4 %) had leg 
artery angioplasty, and 2 (1.9 %) had cerebrovascular dis-
ease. These two individuals also reported history of heart 
attacks, and one of them had a cardiac bypass surgery.
Guideline adherence
Adherence to guideline recommendations is summa-
rized in Table  2. The following results are reported for 
the cohort as a whole: Under the domain of lifestyle rec-
ommendations, 52.7  % of participants reported follow-
ing a recommended diet, 96.8 % did not currently smoke, 
and 70.5  % reported current physical activity. Based on 
clinical exam and laboratory reports, 35.0 % had optimal 
HbA1C  ≤7  % (53  mmol/mol), 47.8  % had blood pres-
sure ≤130/80  mmHg, 57.7  % had LDL-C ≤2.0  mmol/L, 
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and 50 % had optimal BMI <25 kg/m2. In terms of phar-
macotherapy, 98.1 % of participants were eligible for RAS 
inhibitors and 72.5 % of these participants were using an 
ACEi or ARB. Finally, 72.1  % participants reported sta-
tin use. Among all participants, 62.5  % of guideline rec-
ommendations were met, which was the same between 
primary and secondary prevention subgroups. Agree-
ment among each component of the adherence index was 
low (κ < 0.20), except for between statin use and LDL-C 
(κ  =  0.29). The primary and secondary prevention sub-
groups had similar self-reported adherence to all the 
above recommendations except for physical activity and 
statin use. Specifically, compared to the secondary pre-
vention subgroup the primary prevention subgroup had 
significantly higher proportion of participants who were 
physically active and lower prevalence of statin use.
Table 1 Descriptive characteristics of 309 participants with longstanding type 1 diabetes
Data presented as mean ± SD, median [IQR], or n (%) unless otherwise indicated. Percentages were calculated from available data. P values for comparison were 
calculated using the student’s t-test, Mann–Whitney U test, or the χ2 -test depending on variable distribution
MNSI Michigan neuropathy screening instrument, BP blood pressure; HbA1C glycated hemoglobin A1C, ASA acetylsalicylic acid, RAS renin-angiotensin system, ARB 
angiotensin II receptor blocker, ACEi angiotensin-converting-enzyme inhibitor
a Retinopathy as determined by most recent fundoscopy examination results
b Nephropathy defined by age-adjusted GFR <60 ml/min and/or ACR ≥2 mg/mmol
c RASi includes usage of at least one of ARB and ACEi
* Statistically significant p < 0.05
Characteristic Total (n = 309) Primary prevention  
(n = 204)




 Age (year) 65.7 ± 8.5 64.3 ± 8.3 68.5 ± 8.3 <0.001*
 Duration of diabetes (year) 54.0 [51.0, 59.0] 53.0 [50.0, 57.0] 57.0 [52.5, 60.5] <0.001*
 Male [n (%)] 137 (44.5 %) 82 (40.4 %) 55 (52.4 %) 0.045*
 Non-caucasian [n (%)] 13 (4.2 %) 10 (5 %) 3 (2.9 %) 0.40
 Father’s age at death (year) 76.0 [66.0, 85.0] 76.0 [66.0,85.0] 76.5 [63.5, 84.3] 0.66
 Mother’s age at death (year) 85.0 [77.0, 90.0] 85.0 [76.0,90.0] 84.5 [78.3, 90.0] 0.91
 Parent with CVD [n (%)] 171 (56.4 %) 106 (53.3 %) 65 (62.5 %) 0.12
 Sibling with CVD [n (%)] 68 (23.7 %) 38 (20.4 %) 30 (29.7 %) 0.08
Clinical
 BMI (kg/m2) 25.0 [23.0, 28.2] 24.9 [23.0,27.5] 25.7 [22.8, 29.1] 0.33
 Systolic BP (mmHg) 128.8 ± 14.9 128.7 ± 14.6 129.0 ± 15.7 0.91
 Diastolic BP (mmHg) 67.4 ± 8.9 67.8 ± 8.8 66.5 ± 9.1 0.37
 History of hypertension [n (%)] 182 (60.3 %) 111 (56.1 %) 71 (68.3 %) 0.04*
Laboratory
 HbA1c (%) 7.5 ± 1.1 (58 mmol/mol) 7.4 ± 1.1 (57 mmol/mol) 7.7 ± 1.1 (61 mmol/mol) 0.04*
 Total cholesterol (mmol/L) 4.1 ± 0.9 4.24 ± 0.92 3.95 ± 0.86 0.02*
 Triglycerides (mmol/L) 0.80 [0.60, 1.05] 0.77 [0.60, 1.00] 0.83 [0.66, 1.23] 0.04*
 HDL-C (mmol/L) 1.7 ± 0.5 1.79 ± 0.52 1.58 ± 0.49 0.002*
 LDL-C (mmol/L) 2.0 ± 0.7 2.06 ± 0.70 1.92 ± 0.65 0.10
Complications
 Diabetic retinopathy [n (%)]a 193 (71.5 %) 116 (64.4 %) 77 (85.6 %) <0.001*
 Neuropathy (MNSI ≥3) [n(%)] 130 (42.3 %) 71 (34.8 %) 59 (57.3 %) <0.001*
 Nephropathy [n (%)]b 110 (38.6 %) 59 (31.7 %) 51 (51.5 %) 0.001*
Medications
 ASA [n (%)] 177 (58.0 %) 95 (47.5 %) 82 (78.1 %) <0.001*
 Statin [n (%)] 220 (72.1 %) 131 (65.5 %) 89 (84.8 %) <0.001*
 Ezetimibe [n (%)] 23 (7.5 %) 10 (5 %) 13 (12.4 %) 0.02*
 Fibrate [n (%)] 1 (0.3 %) 1 (0.5 %) 0 (0.0 %) 0.47
 RAS inhibitor [n (%)]c 218 (71.5 %) 141 (70.5 %) 77 (73.3 %) 0.60
  ARB [n (%)] 92 (30.2 %) 55 (27.5 %) 37 (35.2 %) 0.16
  ACEi [n (%)] 132 (43.3 %) 90 (45.0 %) 42 (40.0 %) 0.40
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In sensitivity analysis, results did not differ when 
alternate target thresholds were used for HbA1c, blood 
pressure, and BMI. Furthermore, when statin use was 
compared only in participants 75  years or younger, the 
primary prevention subgroup still had significantly lower 
statin prevalence than the secondary prevention sub-
group (117 (65 %) vs 73 (86.9 %), p < 0.001).
Factors associated with statin use
Univariable analyses demonstrated that female sex, 
hypertension history, higher BMI, lower LDL-C, lower 
HDL-C, lower total cholesterol, presence of at least one 
microvascular complication, nephropathy, retinopathy, 
absence of CVD history, acetylsalicylic acid use, and 
RAS inhibitor use were associated with the presence of 
statin use (Table  3). These variables, in addition to age 
and HbA1c, were used to create a multivariable model as 
shown in Table 4, which showed that only a higher cho-
lesterol level (adjusted OR  =  0.39 [0.25, 0.59] per unit 
increase in mmol/L, p < 0.001) and absence of CVD his-
tory (adjusted OR  =  0.38 [0.15, 0.95] for membership 
in primary prevention subgroup, p  =  0.04) were inde-
pendently associated with lower statin use. Both factors 
remained significantly associated with statin after a step-
wise selection process.
When the logistic regression was restricted to partici-
pants in the primary prevention subgroup, sex, age, total 
cholesterol, BMI, RAAS blockade, and aspirin use were 
associated with statin use in univariable analysis. When 
these were included in the multivariable model, only 
lower total cholesterol was significantly associated statin 
use.
Discussion
In the cross-sectional analysis of 309 Canadians with 
longstanding type 1 diabetes uniformly considered to be 
at high CVD risk, we observed similar adherence to most 
general guideline recommendations between the primary 
and secondary prevention subgroups. However, against 
prevailing recommendations, the primary prevention 
subgroup had markedly insufficient statin use—approxi-
mately one-third odds relative to the secondary preven-
tion subgroup. Such odds persisted in adjusted analysis 
to account for potential confounding variables: age, sex, 
hypertension history, greater BMI, higher HbA1c and 
total cholesterol, presence of microvascular complica-
tions, and acetylsalicylic acid and RAS inhibitor use.
Suboptimal self‑reported statin use in the context of the 
literature
Suboptimal statin use has been commonly reported in 
a variety of study populations, and is associated with 
financial, drug-related, health system-related, condition-
related, and patient and physician-related factors [17]. 
Fig. 2 Prevalence of cardiovascular disease (CVD) conditions among the 105 participants with CVD
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Statin use in large clinical trials typically ranges from 
continuation rates of 70–90  % of trial participants [32–
34]. Cross-sectional studies in patients with diabetes in 
real-world clinical settings have reported much lower 
rates, generally approximating 50 % prevalence of statin 
use [35–37]. Most of these studies have been conducted 
in the context of type 2 diabetes, though some limited 
data suggests even lower statin use in type 1 diabetes 
with estimated prevalence below 50  % [38]. Our study 
addresses this paucity of evidence on statin use in type 
1 diabetes by studying individuals with longstanding dia-
betes who are at high CVD risk and uniformly require 
statin use for CVD prevention. It is encouraging to note 
that statin prevalence in our participants (72.1 %) exceeds 
that in most observational studies, and even approaches 
the high rates observed in statin clinical trials. Nonethe-
less, the concern remains that there was a key disparity 
between primary and secondary prevention subgroups, 
with about 20 % lower statin use in those without a his-
tory of CVD. This implies a significant care gap in the 
primary prevention of CVD in patients with type 1 dia-
betes which puts these patients at high risk of a first 
CVD incident [19, 20]. To estimate the potential clinical 
implication of this care gap, a simulation study demon-
strated that a 25 % increase in statin prevalence in a pri-
mary prevention cohort is predicted to avert up to 53 % 
more CVD-related deaths over 10 years [39]. We there-
fore hypothesize that increasing statin use among type 1 
diabetes patients without a history of CVD to approxi-
mate that observed in patients with CVD could represent 
a substantial strategy to reduce CVD mortality. From a 
public health perspective, our results suggest that target-
ing improved statin use in longstanding type 1 diabetes 
presents an opportunity to decrease the CVD incidence 
and mortality.
Comparison to literature for other general guideline 
recommendations
Regarding other CVD prevention recommendations, 
adherence in our participants was similar to that in 
other cross-sectional studies in outpatient diabetes set-
tings [35–37]. In fact, it is reassuring that as a whole, our 
participants had HbA1c, BMI, blood pressure, and lipid 
measures which were close to or better than guideline 
recommendations. Remarkably, our cohort had a RAS 
inhibitor prevalence of 72.5  % amongst eligible partici-
pants–similar between primary and secondary preven-
tion subgroups–which approximates that previously 
found in type 1 diabetes populations [40]. Interestingly, 
high ACEi and ARB use was uniform between the two 
subgroups despite greater prevalence of hypertension 
and nephropathy in the secondary prevention subgroup. 
Table 2 Measures of adherence to CVD prevention guidelines
Data presented as proportion n (%) achieving adherence, calculated as percentage of available data. P values for comparison are calculated using the Mann–Whitney 
U or χ2 -test, depending on variable distribution
a Recommended diet measured by self-reported consumption of fruits and vegetables in addition to moderate consumption of dietary carbohydrates and fats
b Missing blood pressure: 150 (49 %) missing
c RASi includes usage of at least one of ARB and ACEi, percentages calculated out of only for participants who are eligible for RASi (see Methods)
d Statin use percentages calculated out of only participants under age 75 (n = 264), instead of whole cohort (n = 309)
* Statistically significant p < 0.05
Adherence category Total (n = 309) Primary prevention  
(n = 204)




 Recommended dieta 159 (52.7 %) 105 (52.2 %) 54 (53.5 %) 0.84
 Non-smoking 296 (95.8 %) 195 (95.6 %) 101 (96.2 %) 0.80
 Physically active 217 (70.5 %) 154 (75.5 %) 63 (60.6 %) 0.007*
Clinical target attainment
 HbA1c ≤7.0 % 103 (35.0 %) 74 (38.1 %) 29 (29.0 %) 0.12
 Blood pressure ≤130/80 mmHgb 76 (47.8 %) 53 (50.5 %) 23 (42.6 %) 0.35
 LDL-C ≤ 2.0 mmol/L 150 (57.7 %) 95 (54.6 %) 55 (64.0 %) 0.15
 Optimal BMI <25.0 kg/m2 149 (50 %) 101 (51.0 %) 48 (48.0 %) 0.62
Pharmacotherapy adherence
 RAS inhibitorc 221 (72.5 %) 144 (72.0 %) 77 (73.3 %) 0.80
 Statin 220 (72.1 %) 131 (65.5 %) 89 (84.8 %) <0.001*
  Among participants Age <75d 190 (72.0 %) 117 (65.0 %) 73 (86.9 %) <0.001*
Total adherence
 Median percentage of targets met 62.5 (50.0, 75.0) 62.5 (50.0, 75.0) 62.5 (50.0, 77.8) 0.93
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This is in contrast to lower statin use in the primary com-
pared to secondary prevention subgroup, even though 
the two subgroups had similar levels of LDL-C. Perhaps 
this phenomenon suggests a strong recognition by cli-
nicians and patients of the protective benefits of RAS 
inhibition, and in contrast, an incorrect but prevailing 
clinical view that statin use should be limited to those 
with CVD or dyslipidemia. This data strongly supports 
the notion that clinicians and patients may not appreciate 
long diabetes duration as a significant CVD risk factor 
and are thus reluctant to use statin for primary preven-
tion—a view which has been disproven by the results of 
many large studies [7–9].
Study limitations
While this study is the first to investigate attention to 
clinical practice guidelines and self-reported statin use in 
the context of longstanding type 1 diabetes, and it used 
mixed methods of data acquisition including self-report, 
validated questionnaires, and laboratory measures, we 
recognize some limitations and sources of potential bias. 
First, our investigation of extreme diabetes duration car-
ries a risk of selection bias—specifically, incidence-preva-
lence (survival) bias—whereby participants may have had 
better life-long management of CVD risk compared to 
those who did not survive to 50 years diabetes duration. 
However, though the magnitude of adherence and CVD 
prevalence may be affected by such incidence-prevalence 
bias, it is unlikely that it would affect the observed asso-
ciation of statin use and the primary and secondary pre-
vention subgroups. Secondly, we acknowledge the risk of 
recall bias and consequent misclassification error, though 
we expect these to be small in magnitude given the dis-
cernible nature of CVD and current medication use, 
and we emphasize that such recall bias is non-differen-
tial between our analytical subgroups and that the odds 
ratios presented are unlikely to be influenced by this bias. 
Third, ascertainment of cerebrovascular disease events 
may have been incomplete, but the low prevalence of 
these events is in keeping with known rates from epide-
miological study of type 1 diabetes [41]. Fourth, while we 
Table 3 Results of  univariable logistic regression of  vari-
ables associated with statin use in 309 participants
a Presence of at least one of neuropathy, nephropathy, or retinopathy, based on 
objective evidence
* Statistically significant p < 0.05
Variable Odds  
ratio
95 % CI P‑value
Age (per year) 1.01 0.98, 1.04 0.58
Duration of diabetes (per year) 1.02 0.98, 1.06 0.38
Female 0.42 0.24, 0.71 0.001*
Parent with CVD 0.96 0.58, 1.59 0.86
Sibling with CVD 0.63 0.35, 1.13 0.12
History of smoking 1.28 0.77, 2.11 0.34
Physically active 0.86 0.49, 1.5 0.60
History of hypertension 1.69 1.01, 2.82 0.047*
BMI (per kg/m2) 1.1 1.03, 1.18 0.006*
HbA1c (per  %) 1.09 0.86, 1.4 0.47
LDL-C (per mmol/L) 0.25 0.15, 0.41 <0.001*
HDL-C (per mmol/L) 0.44 0.26, 0.77 0.004*
Triglycerides (per mmol/L) 1.2 0.68, 2.15 0.53
Total cholesterol (per mmol/L) 0.35 0.24, 0.5 <0.001*
Microvascular complicationa 2.21 1.19, 4.11 0.01*
 Neuropathy 1.14 0.68, 1.89 0.62
 Nephropathy 1.89 1.05, 3.39 0.03*
 Retinopathy 2.04 1.16, 3.6 0.01*
Absence of CVD history 0.34 0.19, 0.63 <0.001*
ASA 3.44 2.04, 5.8 <0.001*
RASi 2.82 1.66, 4.81 <0.001*
 ARB 1.89 1.05, 3.41 0.04*
 ACEi 1.7 1.01, 2.86 0.046*
Table 4 Results of  multivariable logistic regression, with   
statin use as the dependent variable
237 (77 %) out of 309 possible observations had sufficient data to be included 
in this analysis
Model 1: All significant variables from univariable analysis included, with the 
exception of LDL and HDL, due to multicollinearity with total cholesterol. All 
microvascular complications were represented by presence of microvascular 
complication and ARB/ACEi were represented by RASi in the multivariable 
model. Age and HbA1c were forced into the model
Model 2: As a sensitivity analysis, stepwise selection process was used to decide 
on final model, with choice of variables the same as Model 1
a Sensitivity analysis using SBP instead of history of hypertension resulted in 
an adjusted odds ratio for absence of CVD history of 0.36 (95 % CI 0.11, 1.13, 
p = 0.07)
* Statistically significant p < 0.05




 Age (per year) 1.00 0.96, 1.05 0.86
 Female 1.09 0.52, 2.32 0.81
 History of hypertensiona 0.81 0.36, 1.80 0.60
 BMI (per kg/m2) 1.03 0.94, 1.13 0.56
 HbA1c (per  %) 1.19 0.85, 1.66 0.31
 Total cholesterol (per mmol/L) 0.39 0.25, 0.59 <0.001*
 Microvascular complication 1.55 9.64, 3.73 0.33
 Absence of CVD history 0.38 0.15, 0.95 0.04*
 ASA 1.80 0.89, 3.63 0.10
 RASi 1.75 0.78, 3.93 0.17
Model 2
 Absence of CVD history 0.28 0.12, 0.63 0.002*
 Total cholesterol (per mmol/L) 0.39 0.26, 0.56 <0.001*
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believe that our analysis has considered the most funda-
mental confounders through adjustment, there remains 
the possibility of unmeasured and residual confounding. 
For instance, other studies have found retirement and 
female sex to be associated with lower adherence to sta-
tin use and prescription, respectively, [42, 43]; these vari-
ables may require further study in our cohort. Fifth, as 
this study was a secondary analysis, we only determined 
prevalence of statin use rather than a direct measure of 
medication adherence such as proportion of days cov-
ered by statin prescriptions or reasons—such as medica-
tion side-effects—for statin non-use. Finally, our results 
are specific to those with longstanding type 1 diabetes 
and may not extend to T2DM or older adult populations 
without diabetes.
Conclusions
Adherence to cardiovascular protection guidelines—
especially statin use—is of fundamental clinical impor-
tance because under-treatment in high-risk individuals 
can worsen cardiovascular disease risk and increase the 
burden to the healthcare system [17, 23]. This study sup-
ports that Canadians with longstanding type 1 diabetes 
have relatively high self-reported adherence to guidelines 
and statin prevalence as a whole, but there is inappropri-
ately lower statin use for CVD primary prevention than 
secondary prevention. In view of this apparent clini-
cal disregard for longstanding diabetes as a fundamen-
tal CVD risk factor, our results may serve to encourage 
improved adherence to evidence-based recommenda-
tions for primary prevention of CVD with statins in this 
population. Future research with this unique cohort 
should focus on elucidating the causes of suboptimal sta-
tin use, and interventions should address statin dispar-
ity between primary and secondary CVD prevention in 
patients with longstanding type 1 diabetes.
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